CN102429993B - Compound oral liquid for treating poultry colibacillosis mixed infection - Google Patents
Compound oral liquid for treating poultry colibacillosis mixed infection Download PDFInfo
- Publication number
- CN102429993B CN102429993B CN 201110400906 CN201110400906A CN102429993B CN 102429993 B CN102429993 B CN 102429993B CN 201110400906 CN201110400906 CN 201110400906 CN 201110400906 A CN201110400906 A CN 201110400906A CN 102429993 B CN102429993 B CN 102429993B
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- mixed infection
- treatment
- compound oral
- colibacillosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of animal medicines, and in particular discloses compound oral liquid for treating poultry colibacillosis mixed infection. Each 100L of compound oral liquid for treating poultry colibacillosis mixed infection consists of the following components: 15 to 25L of heartleaf houttuynia herb distillate, 0.5 to 1kg of amikacin sulfate, 0.5 to 1kg of gentamicin sulfate, 0.05 to 0.2kg of trimethoprim lactate, 3 to 8kg of nicotinamide, 0.01 to 0.05kg of dexamethasone sodium phosphate, 0.1 to 0.3kg of sodium hydrogensulfite, 0.1 to 0.5L of lactic acid and the balance of purified water. The compound oral liquid for treating poultry colibacillosis mixed infection has the advantages that: antibacterial and antiviral effects are obvious, and poultry persistent fever symptoms caused by poultry colibacillosis mixed infection can be relieved, so that the organism function of poultry is quickly recovered; and the oral liquid has quick response and an obvious curative effect and is conveniently and safely used.
Description
Technical field
The present invention relates to the animal-use drug technical field, be specifically related to a kind of compound oral liquid for the treatment of avian colibacillosis mixed infection.
Background technology
Poultry disease morbidity in recent years presents mixed infection trend, be widely current as mixed infection diseases such as avian escherichia coli and newcastle, escherichia coli and infectious bronchitis, infectious bursa of Fabricius and newcastle, influenza and newcastles, cause the state of an illness complicated, brought great difficulty to diagnoses and treatment, also made the raiser suffer great economic loss simultaneously.Show according to investigations, the most common with avian colibacillosis mixed infection in the birds mixed infection disease, avian colibacillosis mixed infection at present all is widely current in most of plants, M ﹠ M is high, a lot of local trend that have been outbreak of epidemic, main clinical manifestation are that lethargy, feed intake descend; Snore, mouth breathing; The green loose stool of row's HUANGBAI(sic); Laying rate of laying hen descends; And symptoms such as mortality appear.Show that according to clinical research numerous disease can cause secondary or the mixed infection of avian colibacillosis, as infectious bronchitis of chicken, laryngotracheitis, newcastle, salmonellosis, mycoplasma, infective rhinitis etc.At present, avian colibacillosis mixed infection has badly influenced the sound development that fowl already produces, therefore also occurred many medicines that are used for the treatment of avian colibacillosis mixed infection in the market, but still had following problems, as onset is slow, therapeutic effect is not good, expensive etc.
Summary of the invention
The object of the present invention is to provide a kind of compound oral liquid for the treatment of avian colibacillosis mixed infection.
In order to realize above purpose, the technical solution used in the present invention is: a kind of compound oral liquid for the treatment of avian colibacillosis mixed infection, every 100L oral liquid is composed of the following components: Herba Houttuyniae distillate 15～25L, amikacin sulfate 0.5～1kg, gentamycin sulfate 0.5～1kg, Trimethoprim lactate 0.05～0.2kg, nicotiamide 3～8kg, dexamethasone sodium phosphate 0.01～0.05kg, sodium sulfite 0.1～0.3kg, lactic acid 0.1～0.5L, surplus is purified water.
Preferably, the every 100L of compound oral liquid for the treatment of avian colibacillosis mixed infection is composed of the following components: Herba Houttuyniae distillate 20L, amikacin sulfate 0.5～1kg, gentamycin sulfate 0.5～1kg, Trimethoprim lactate 0.05～0.2kg, nicotiamide 3～8kg, dexamethasone sodium phosphate 0.01～0.02kg, sodium sulfite 0.1～0.3kg, lactic acid 0.3L, surplus is purified water.
Further preferred, the every 100L of compound oral liquid for the treatment of avian colibacillosis mixed infection is composed of the following components: Herba Houttuyniae distillate 20L, amikacin sulfate 0.833kg, gentamycin sulfate 0.833kg, Trimethoprim lactate 0.167kg, nicotiamide 5kg, dexamethasone sodium phosphate 0.015kg, sodium sulfite 0.2kg, lactic acid 0.3L, surplus is purified water.
In the compound oral liquid for the treatment of avian colibacillosis provided by the invention mixed infection, effects such as that the Herba Houttuyniae distillate has is antibiotic, antiviral, antiinflammatory, Herba Houttuyniae distillate and gentamycin sulfate, amikacin sulfate, Trimethoprim lactate, dexamethasone sodium phosphate use in conjunction, have collaborative, potentiation, antibiotic, antiphlogistic effects is remarkable.
The compound oral liquid for the treatment of avian colibacillosis provided by the invention mixed infection has the following advantages: antibiotic, antivirus action is remarkable, and can solve the birds persistent fever symptom that avian colibacillosis mixed infection causes, make the fast quick-recovery of fowl body function; Rapid-action, evident in efficacy, easy to use, safe.
The compound oral liquid for the treatment of avian colibacillosis provided by the invention mixed infection is applicable to effective treatment of birds colibacillosis mixed infections such as chicken, duck, goose.
The specific embodiment
Below by embodiment technical scheme of the present invention is further specified.
The various raw materials of using in following examples all are commercial goods.
Embodiment 1
The compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides, every 100L oral liquid is composed of the following components: Herba Houttuyniae distillate 15L, amikacin sulfate 1kg, gentamycin sulfate 0.5kg, Trimethoprim lactate 0.2kg, nicotiamide 3kg, dexamethasone sodium phosphate 0.01kg, sodium sulfite 0.1kg, lactic acid 0.1L, surplus is purified water.
The preparation method of the compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides is as follows:
(1) accurately measures Herba Houttuyniae distillate 15L, lactic acid 0.1L, take by weighing amikacin sulfate 1kg, gentamycin sulfate 0.5kg, Trimethoprim lactate 0.2kg, nicotiamide 3kg, dexamethasone sodium phosphate 0.01kg, sodium sulfite 0.1kg;
(2) measure the purified water of 50L, the amikacin sulfate, gentamycin sulfate, Trimethoprim lactate, nicotiamide, dexamethasone sodium phosphate, the sodium sulfite that take by weighing in the step (1) are added in the purified water of measuring successively according to the sequencing of sodium sulfite, amikacin sulfate, gentamycin sulfate, Trimethoprim lactate, nicotiamide, dexamethasone sodium phosphate, stir, get solution A;
(3) the Herba Houttuyniae distillate of measuring in the step (1) is put into solution A, mix homogeneously gets solution B;
(4) add the lactic acid that step (1) is measured in solution B, stir, regulating pH value then is 4.5, add purified water again and be settled to 100L, filter, embedding, in 115 ℃ of flowing steam sterilizations 30 minutes, namely get the compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides.
Embodiment 2
The compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides, every 100L oral liquid is composed of the following components: Herba Houttuyniae distillate 25L, amikacin sulfate 0.5kg, gentamycin sulfate 1kg, Trimethoprim lactate 0.05kg, nicotiamide 8kg, dexamethasone sodium phosphate 0.05kg, sodium sulfite 0.3kg, lactic acid 0.5L, surplus is purified water.
The preparation method of the compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides is as follows:
(1) accurately measures Herba Houttuyniae distillate 25L, lactic acid 0.5L, take by weighing amikacin sulfate 0.5kg, gentamycin sulfate 1kg, Trimethoprim lactate 0.05kg, nicotiamide 8kg, dexamethasone sodium phosphate 0.05kg, sodium sulfite 0.3kg;
(2) measure the purified water of 50L, the amikacin sulfate, gentamycin sulfate, Trimethoprim lactate, nicotiamide, dexamethasone sodium phosphate, the sodium sulfite that take by weighing in the step (1) are added in the purified water of measuring successively according to the sequencing of sodium sulfite, amikacin sulfate, gentamycin sulfate, Trimethoprim lactate, nicotiamide, dexamethasone sodium phosphate, stir, get solution C;
(3) the Herba Houttuyniae distillate of measuring in the step (1) is put into solution C, mix homogeneously gets solution D;
(4) add the lactic acid that step (1) is measured in solution D, stir, regulating pH value then is 5.0, add purified water again and be settled to 100L, filter, embedding, in 115 ℃ of flowing steam sterilizations 30 minutes, namely get the compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides.
Embodiment 3
The compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides, every 100L oral liquid is composed of the following components: Herba Houttuyniae distillate 20L, amikacin sulfate 1kg, gentamycin sulfate 0.5kg, Trimethoprim lactate 0.1kg, nicotiamide 5kg, dexamethasone sodium phosphate 0.02kg, sodium sulfite 0.2kg, lactic acid 0.3L, surplus is purified water.
The preparation method of the compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides is as follows:
(1) accurately measures Herba Houttuyniae distillate 20L, lactic acid 0.3L, take by weighing amikacin sulfate 1kg, gentamycin sulfate 0.5kg, Trimethoprim lactate 0.1kg, nicotiamide 5kg, dexamethasone sodium phosphate 0.02kg, sodium sulfite 0.2kg;
(2) measure the purified water of 50L, the amikacin sulfate, gentamycin sulfate, Trimethoprim lactate, nicotiamide, dexamethasone sodium phosphate, the sodium sulfite that take by weighing in the step (1) are added in the purified water of measuring successively according to the sequencing of sodium sulfite, amikacin sulfate, gentamycin sulfate, Trimethoprim lactate, nicotiamide, dexamethasone sodium phosphate, stir, get solution E;
(3) the Herba Houttuyniae distillate of measuring in the step (1) is put into solution E, mix homogeneously gets solution F;
(4) add the lactic acid that step (1) is measured in solution F, stir, regulating pH value then is 4.8, add purified water again and be settled to 100L, filter, embedding, in 115 ℃ of flowing steam sterilizations 30 minutes, namely get the compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides.
Embodiment 4
The compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides, every 100L oral liquid is composed of the following components: Herba Houttuyniae distillate 20L, amikacin sulfate 0.833kg, gentamycin sulfate 0.833kg, Trimethoprim lactate 0.167kg, nicotiamide 5kg, dexamethasone sodium phosphate 0.015kg, sodium sulfite 0.2kg, lactic acid 0.3L, surplus is purified water.
The preparation method of the compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides is as follows:
(1) accurately measures Herba Houttuyniae distillate 20L, lactic acid 0.3L, take by weighing amikacin sulfate 0.833kg, gentamycin sulfate 0.833kg, Trimethoprim lactate 0.167kg, nicotiamide 5kg, dexamethasone sodium phosphate 0.015kg, sodium sulfite 0.2kg;
(2) measure the purified water of 50L, the amikacin sulfate, gentamycin sulfate, Trimethoprim lactate, nicotiamide, dexamethasone sodium phosphate, the sodium sulfite that take by weighing in the step (1) are added in the purified water of measuring successively according to the sequencing of sodium sulfite, amikacin sulfate, gentamycin sulfate, Trimethoprim lactate, nicotiamide, dexamethasone sodium phosphate, stir, get solution G;
(3) the Herba Houttuyniae distillate of measuring in the step (1) is put into solution G, mix homogeneously gets Solution H;
(4) add the lactic acid that step (1) is measured in Solution H, stir, regulating pH value then is 4.7, add purified water again and be settled to 100L, filter, embedding, in 115 ℃ of flowing steam sterilizations 30 minutes, namely get the compound oral liquid of the treatment avian colibacillosis mixed infection that present embodiment provides.
The consumption of the compound oral liquid of the treatment avian colibacillosis mixed infection that embodiment 1-embodiment 4 provides is: according to the poultry body weight, and dose 5ml/kg, 2 times on the one, five days is a course for the treatment of.
The test example
The clinical trial of the compound oral liquid of the treatment avian colibacillosis mixed infection that embodiment 1-embodiment 4 provides
The compound oral liquid treatment chicken colibacillosis mixed infection newcastle of the treatment avian colibacillosis mixed infection that test example 1 usefulness embodiment of the invention 1-embodiment 4 provides;
1. experimental animal: 3000 the 12 age in days AA broiler chicken in chicken farm, Zhoukou City, Henan Province are colibacillosis mixed infection newcastle through clinical and laboratory comprehensive diagnos;
2. the compound oral liquid of the treatment avian colibacillosis mixed infection that test medication: embodiment of the invention 1-4 provides;
The contrast medication: commercially available certain compound oral liquid, effective ingredient are gentamycin sulfate and amikacin sulfate;
3. test method: 3000 sick chickens are divided into 6 groups at random, 500 every group; The 1st group of sick chicken used the compound oral liquid of the treatment avian colibacillosis mixed infection that medicine provides as embodiment 1, the 2nd group of sick chicken used the compound oral liquid of the treatment avian colibacillosis mixed infection that medicine provides as embodiment 2, the 3rd group of sick chicken used the compound oral liquid of the treatment avian colibacillosis mixed infection that medicine provides as embodiment 3, the 4th group of sick chicken used the compound oral liquid of the treatment avian colibacillosis mixed infection that medicine provides as embodiment 4, and administrated method concentrates drinking-water to treat after being compound oral liquid dilute with water twice with the mixed infection for the treatment of avian colibacillosis; The 5th group of sick chicken uses medicine to be the contrast medication, and administrated method is to concentrate the drinking-water treatment after will contrasting medication dilute with water twice; The 6th group of sick chicken is blank group, do not take any treatment measure;
4. efficacy determination: after the treatment beginning, the health situation of change that records chicken every day distributes, and treats after the 5th day and adds up therapeutic effect;
Curative effect judging standard is as follows:
Invalid: after 5 days, ill chicken symptom does not have obvious change, still keeps the preceding symptom for the treatment of or ill chicken death;
Effectively: after 5 days, ill chicken spirit takes a turn for the better, and it is normal that feed intake is recovered;
5. clinical trial result
The statistical result of clinical application observation of curative effect is shown in Table 1, as can be seen from Table 1,1st, 2,3,4,5 groups of sick chickens are compared with the 6th group of sick chicken and have all obtained treatment to a certain degree, and compound oral liquid and the contrast medication of the treatment avian colibacillosis mixed infection that this explanation embodiment of the invention 1-embodiment 4 provides all can be treated chicken colibacillosis mixed infection newcastle.Be it can also be seen that by table 1, adopt the treatment effective percentage of the compound oral liquid of the treatment avian colibacillosis mixed infection that embodiment of the invention 1-embodiment 4 provides all to be significantly higher than the treatment effective percentage that adopts the contrast medication, illustrate that the curative effect of compound oral liquid of the treatment avian colibacillosis mixed infection that embodiment of the invention 1-embodiment 4 provides is significantly better than contrasting medication.In addition, be it can also be seen that by table 1, the treatment effective percentage of the compound oral liquid of the treatment avian colibacillosis mixed infection that embodiment of the invention 1-embodiment 4 provides differs less, illustrates that the therapeutic effect of compound oral liquid of the treatment avian colibacillosis mixed infection that embodiment of the invention 1-embodiment 4 provides is definite, stable.
Table 1 clinical application observation of curative effect statistical result (the 5th day statistical result)
| Group | Number of elements | Invalid dead number of elements | Mortality rate | Effective number of elements | Effective percentage |
| 1 | 500 | 7 | 1.4％ | 493 | 98.6％ |
| 2 | 500 | 8 | 1.6％ | 492 | 98.4％ |
| 3 | 500 | 5 | 1.0％ | 495 | 99.0％ |
| 4 | 500 | 3 | 0.6％ | 497 | 99.4％ |
| 5 | 500 | 173 | 34.6％ | 327 | 65.4％ |
| 6 | 500 | 277 | 55.4％ | 223 | 44.6％ |
The compound oral liquid treatment duck colibacillosis mixed infection duck pestilence observation of curative effect of the treatment avian colibacillosis mixed infection that the test example 2 usefulness embodiment of the invention 4 provide;
Treatment animal: the meat-type duck in 2000 4 of Xinyang, Henan Province Huangchuan duckeries ages in week
Medicine for treatment: the compound oral liquid of the treatment avian colibacillosis mixed infection that the embodiment of the invention 4 provides;
Diagnostic criteria: sick duck lassitude, happiness is crouched, and is slow in action, and abdominal part has significantly sagging during walking, shed tears and blepharoedema, flow out the secretions of thin or thickness in the nose, dyspnea, the part duck sees cough, discharges green or canescence loose stool, and the perianal feather is stain or lumps.In the sick duck later stage of part, swelling in various degree takes place in visible head and footpath portion, and tactile have a fluctuation.Analyse that visible airbag wall thickens, muddiness, there is caseous exudate on the surface, and pericardiosymphysis is full of faint yellow fibrinous exudate in the pericardium capsule; Liver enlargement, surface have the faint yellow or milk yellow cellulose membrane of one deck; Esophagus expands partly has the downright bad band of a lark or hemorrhage band with the glandular stomach intersection, and muscular stomach cutin membrane lower floor is congested and hemorrhage.Intestinal mucosa hyperemia, hemorrhage, the most serious with rectum and duodenum.
Therapeutic Method: every duck is pressed body weight, dose 5ml/kg, and 2 times on the one, five days is a course for the treatment of.Strengthen feeding and management simultaneously.
Therapeutic effect: medication is after 3 days, and sick duck spirit takes a turn for the better, and respiratory symptom disappears, and feces is tending towards normally, and indivedual ducks have the ataxia phenomenon.After the medication 5 days, sick duck symptom all disappears, and full group takes a turn for the better.
The compound oral liquid treatment pigeon colibacillosis mixed infection influenza observation of curative effect of the treatment avian colibacillosis mixed infection that the test example 3 usefulness embodiment of the invention 4 provide;
The treatment animal: 500 adult Columba livias of Columba livia association are supported in the Kaifeng;
Diagnostic criteria: because temperature descends suddenly, do not do warming measure, cause the Columba livia group to catch cold, sick Columba livia begins to draw the yellow green loose stool, engenders that feed intake descends, and is slow-witted upright, is reluctant to take off, and ataxia appears in the part pigeon, snore, and crop does not have food.Analysing disease Columba livia larynx has a large amount of mucus, and trachea has ring-type hemorrhage, and airbag wall thickens, muddiness, and there is yellow caseous exudate on the surface, the spleen enlargement, and intestinal mucosa comes off, and duodenum has hemorrhage.Be diagnosed as colibacillosis mixed infection influenza in conjunction with morbidity history and laboratory diagnosis.
Therapeutic Method: every pigeon is pressed body weight, dose 2.5ml/kg, and 2 times on the one, five days is a course for the treatment of.Strengthen warming measure simultaneously, improve daily ration, observe and record the degree of getting well of pigeon.
Therapeutic effect: use this medicine after 3 days, sick Columba livia feed intake increases, and ataxia, snore phenomenon reduce.Medication is after 2 days again, and sick Columba livia symptom all disappears, state of an illness control.
Mo Shi bacillus observation of curative effect in the compound oral liquid treatment goose colibacillosis mixed infection of the treatment avian colibacillosis mixed infection that the test example 4 usefulness embodiment of the invention 4 provide;
Treatment animal: the red hat goose in age 1500 7 weeks of foster goose field, table mountain, Henan Province
Medicine for treatment: the compound oral liquid of the treatment avian colibacillosis mixed infection that the embodiment of the invention 4 provides;
Diagnostic criteria: sick goose spirit is depressed, anorexia, and the lower limb weakness is lain prostrate or is the sitting position of dog gesture, and spastic nod or head sways from side to side is circus movement when getting a fright.Analyse visible pericardial effusion, pericardium thickens; The torso bag muddiness has the cheesy exudate of canescence individually, the gallbladder enlargement; The spleen necrosis, the meninges edema.According to epidemiology, clinical diagnosis and laboratory antibacterial isolation identification are judged to be Mo Shi bacillus in the colibacillosis mixed infection.
Therapeutic Method: every goose is pressed body weight, dose 5ml/kg, and 2 times on the one, five days is a course for the treatment of.Strengthen feeding and management simultaneously.
Therapeutic effect: medication is after 3 days, and sick goose symptom all disappears, and full group takes a turn for the better.
It is remarkable to prove fully that by above test example the present invention is used for the treatment of the escherichia coli mixed infection case effects of poultry such as chicken, duck, goose, pigeon, and easy to use, safe.
Claims (3)
1. compound oral liquid for the treatment of avian colibacillosis mixed infection, it is characterized in that, every 100L oral liquid is composed of the following components: Herba Houttuyniae distillate 15～25L, amikacin sulfate 0.5～1kg, gentamycin sulfate 0.5～1kg, Trimethoprim lactate 0.05～0.2kg, nicotiamide 3～8kg, dexamethasone sodium phosphate 0.01～0.05kg, sodium sulfite 0.1～0.3kg, lactic acid 0.1～0.5L, surplus is purified water.
2. the compound oral liquid for the treatment of avian colibacillosis according to claim 1 mixed infection, it is characterized in that, every 100L oral liquid is composed of the following components: Herba Houttuyniae distillate 20L, amikacin sulfate 0.5～1kg, gentamycin sulfate 0.5～1kg, Trimethoprim lactate 0.05～0.2kg, nicotiamide 3～8kg, dexamethasone sodium phosphate 0.01～0.02kg, sodium sulfite 0.1～0.3kg, lactic acid 0.3L, surplus is purified water.
3. the compound oral liquid for the treatment of avian colibacillosis according to claim 1 and 2 mixed infection, it is characterized in that, every 100L oral liquid is composed of the following components: Herba Houttuyniae distillate 20L, amikacin sulfate 0.833kg, gentamycin sulfate 0.833kg, Trimethoprim lactate 0.167kg, nicotiamide 5kg, dexamethasone sodium phosphate 0.015kg, sodium sulfite 0.2kg, lactic acid 0.3L, surplus is purified water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110400906 CN102429993B (en) | 2011-12-06 | 2011-12-06 | Compound oral liquid for treating poultry colibacillosis mixed infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110400906 CN102429993B (en) | 2011-12-06 | 2011-12-06 | Compound oral liquid for treating poultry colibacillosis mixed infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102429993A CN102429993A (en) | 2012-05-02 |
| CN102429993B true CN102429993B (en) | 2013-08-21 |
Family
ID=45978578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110400906 Active CN102429993B (en) | 2011-12-06 | 2011-12-06 | Compound oral liquid for treating poultry colibacillosis mixed infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102429993B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948692B (en) * | 2014-05-14 | 2016-09-07 | 广西南宁市桃源兽药厂 | A kind of livestock and poultry compound medicine containing the radix paeoniae rubrathe and amikacin |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422526A (en) * | 2007-11-02 | 2009-05-06 | 天津瑞普生物技术集团有限公司 | Traditional Chinese medicine oral liquid for treating poultry colibacillosis |
-
2011
- 2011-12-06 CN CN 201110400906 patent/CN102429993B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422526A (en) * | 2007-11-02 | 2009-05-06 | 天津瑞普生物技术集团有限公司 | Traditional Chinese medicine oral liquid for treating poultry colibacillosis |
Non-Patent Citations (2)
| Title |
|---|
| 谭宝秀等.鱼腥草挥发油的提取及其抑菌效果研究.《邵阳学院学报(自然科学版)》.2005,第2卷(第01期), |
| 鱼腥草挥发油的提取及其抑菌效果研究;谭宝秀等;《邵阳学院学报(自然科学版)》;20050330;第2卷(第01期);80-82 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102429993A (en) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101584747B (en) | Antibacterial antivirus Chinese medicinal composition for animal | |
| CN102302599A (en) | Chinese medicinal composition for preventing and treating porcine diarrhea | |
| CN103463346B (en) | Medicine for treating chicken respiratory disease and preparation method thereof | |
| CN104739963A (en) | Preparation method of Chinese medicinal micro-ecological oral preparation for preventing chicken colibaciuosis | |
| CN102895326B (en) | Traditional Chinese medicine composition for treating infantile common cold and preparation method for traditional Chinese medicine composition | |
| CN105709081B (en) | Pharmaceutical composition for treating infectious rhinitis of chicken, application and feed thereof | |
| CN105943629A (en) | Traditional Chinese medicine compound preparation for treating piglet diarrhea and preparation method thereof | |
| CN102429993B (en) | Compound oral liquid for treating poultry colibacillosis mixed infection | |
| CN101780270A (en) | Compound soluble powder for treating respiratory diseases of birds | |
| CN102600282B (en) | Medicament for treating cold and deficiency type calf diarrhea and preparation method thereof | |
| CN104585511B (en) | Prevent the feed addictive of birds influenza pestilence | |
| CN102813910B (en) | Medicine composition used for controlling poultry airsacculitis, and preparation method thereof | |
| CN102008513A (en) | Method for controlling high swine fever by using nose atomization microecological preparation | |
| CN103417571A (en) | Composition for treating chicken mycoplasma respiratory infection and preparing method thereof | |
| CN102813909A (en) | Compound doxycycline hydrochloride composition for preventing and treating colibacillosis and chronic respiratory disease of poultry as well as preparation method thereof | |
| CN113476552A (en) | Medicine for treating respiratory diseases of cultured animals and preparation method thereof | |
| CN101972325A (en) | Medicament composition for treating chick coccidiosis and preparation method thereof | |
| CN106071090A (en) | A kind of anti-diarrhea Chinese medicine compound feed additive and preparation method and application | |
| CN108743697A (en) | A kind of application of littleleaf indianmulberry root and stem extract in treating acute viral pharyngitis | |
| CN101530405A (en) | Citric acid and compound citric acid application in pharmacy | |
| CN110755604A (en) | Pharmaceutical composition for preventing and treating poultry adenofibromyositis and application thereof | |
| CN105943540B (en) | A kind of purposes of simiarenol | |
| CN110974878B (en) | Traditional Chinese medicine spray for treating avian infectious rhinotracheitis of green-shell laying hens and preparation method thereof | |
| CN113491670B (en) | Detoxifying oral liquid for livestock and preparation method thereof | |
| CN104586874B (en) | It is a kind of to be used to prevent and treat medicine of fowl respiratory tract infection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: Minggang office, Zhengzhou Airport Economic Comprehensive Experimental Zone, Zhengzhou City, Henan Province Patentee after: Zhengzhou Bary Animal Pharmaceutical Co., Ltd. Address before: 450000, Henan Province, Zhengzhou City, Xinzheng Province on the north side of the eight thousand rural new highway Patentee before: Zhengzhou Bary Animal Pharmaceutical Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |